Latest Delivery Technology News

SenSen Networks has reported its first full year of positive operating cash flow, driven by strong growth in its Smart Cities segment and strategic cost reductions.

Locate Technologies Limited has responded to an ASX inquiry about unusual trading activity, confirming no undisclosed information and compliance with listing rules. The company points to recent capital raising announcements as context for the share price movement.

Mayne Pharma shareholders have overwhelmingly approved a scheme for Cosette Pharmaceuticals to acquire the company, setting the stage for a pivotal court hearing later this year.

Locate Technologies Limited has raised $316,500 by issuing 2.4 million shares to Novus Capital under its At-the-Market Facility, aiming to bolster its balance sheet amid ongoing growth in last-mile delivery technology.

EVE Health Group has completed its acquisition of Nextract Pty Ltd, positioning itself to enter the lucrative erectile dysfunction and dysmenorrhea markets with innovative drug delivery technologies.

EVE Health Group has successfully passed all shareholder resolutions at its recent General Meeting, paving the way for its acquisition of Nextract Pty Ltd and announcing significant leadership changes.

LTR Pharma has partnered with Strategic Drug Solutions to co-develop OROFLOW®, a novel intranasal spray aimed at providing fast symptom relief for Oesophageal Motility Disorders, tapping into a growing $4.5 billion global market.

Zoom2u Technologies reports steady group revenue with Locate2u growing 10%, supported by AI initiatives that cut staff costs and a $0.5 million capital raise.

RLF AgTech has completed a $2.4 million capital raise through an Entitlement Issue and Shortfall Placement, positioning the company for growth in Australia’s agricultural sector.

RLF AgTech Ltd has successfully raised approximately $2.42 million through an Entitlement Issue and Shortfall Placement, reflecting strong shareholder confidence in its turnaround strategy and growth prospects in Australia and Asia.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for Autosomal Dominant Optic Atrophy, marking a pivotal step in developing a treatment for this currently untreatable blinding disease.

Biome Australia Limited has expanded its distribution footprint to over 6,000 health retail and practitioner locations, marking a 20% increase in six months and advancing toward its Vision 27 target of 8,000 sites by FY27.